SLC27A2 and neoplasm: Combined treatment with the FATP2 inhibitor lipofermata and checkpoint inhibitors anti-CTLA-4 or anti-CSF-1R inhibitors abolished the inhibitory activity of PMN-MDSCs and blocked tumor progression in mice [85].